Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of NBP607 influenza vaccine in healthy adults
NCT03893669Phase 1Completed
- Sponsor
- SK Chemicals
- Start
- Sep 2012
- Primary completion
- Oct 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NBP607-V in influenza (2 arms), sponsored by SK Chemicals. Primary endpoints: Incidence rate of solicited local adverse events at 21 days, Incidence rate of solicited systemic adverse events at 21 days and 7 more. Started Sep 2012; status: completed.
02
Drugs
NBP607-V
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03893669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893669.